Free, no account
Can these run in one protocol?
Same body, not same vial — the syringe planner answers that one. Every pair is read against curated pairs, class rules, and the two records’ own mechanisms; a pair nothing covers says “nothing on record” rather than pretending silence is safety.
Last updated
14things the records argue against
- Dimensions answered
- 7 of 8
- Pairs assessed
- 10
- Points in favour
- 2
A dimension counts as answered when it produced a result — including “checked, nothing found”, which is an answer.
An editorial read on this specific combination — phasing, redundancy across the whole stack, and the blood work a clinician could raise — is written on request by Corbin AI. It needs JavaScript. Every pair above is assessed from our own records either way.
- CJC-1295 no-DAC runs up to 21/week
- TB-500 runs as little as 2/week
- a 11x spread across one protocol
A vial carries a 28-day beyond-use date from first puncture; the slower compound may be discarded part-used.
On record — a curated pair, a label, or a study of the combination.
Every pair, every dimension 10
BPC-157 + TB-5002 conflicts
Both mechanism records read; neither names the other or a shared clearance route.
- both records name VEGFA
- both increases it
- at least one acts through it rather than binding it, so this is additive rather than duplicated
Two compounds pushing the same node the same way. Whether that is wanted depends on the node.
Derived from the two records’ own mechanism fields. No study administered them together.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
- both records carry an adverse effect in the same organ system (systemic)
- but they are different effects: Theoretical concern that a pro-angiogenic signal is undesirable where unwanted vessel growth matters / Lethargy in the days after the first administrations - user-reported and uncontrolled, not a graded observation
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
BPC-157 + CJC-1295 no-DAC1 conflict
Both mechanism records read; neither names the other or a shared clearance route.
Both target sets read; no overlap survives the generic-entity filter.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
- both records carry an adverse effect in the same organ system (cardiovascular)
- but they are different effects: Blood pressure movement in either direction under NO-system challenge in rats / Transient flushing after injection
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
BPC-157 + Ipamorelin2 conflicts
Both mechanism records read; neither names the other or a shared clearance route.
- both records name GASTRIC_MOTILITY
- both increases it
- at least one acts through it rather than binding it, so this is additive rather than duplicated
Two compounds pushing the same node the same way. Whether that is wanted depends on the node.
Derived from the two records’ own mechanism fields. No study administered them together.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
- both records carry an adverse effect in the same organ system (cardiovascular)
- but they are different effects: Blood pressure movement in either direction under NO-system challenge in rats / Transient flushing or lightheadedness after intravenous administration
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
BPC-157 + MK-6771 conflict
Both mechanism records read; neither names the other or a shared clearance route.
Both target sets read; no overlap survives the generic-entity filter.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
- both records carry an adverse effect in the same organ system (cardiovascular)
- but they are different effects: Blood pressure movement in either direction under NO-system challenge in rats / Congestive heart failure reported in a frail elderly hip-fracture population
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
TB-500 + CJC-1295 no-DACno conflict found
Both mechanism records read; neither names the other or a shared clearance route.
Both target sets read; no overlap survives the generic-entity filter.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
Both side-effect profiles read; no overlapping effect, organ system or mechanism.
TB-500 + Ipamorelinno conflict found
Both mechanism records read; neither names the other or a shared clearance route.
Both target sets read; no overlap survives the generic-entity filter.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
Both side-effect profiles read; no overlapping effect, organ system or mechanism.
TB-500 + MK-677no conflict found
Both mechanism records read; neither names the other or a shared clearance route.
Both target sets read; no overlap survives the generic-entity filter.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
Both side-effect profiles read; no overlapping effect, organ system or mechanism.
CJC-1295 no-DAC + Ipamorelin2 conflicts
Both mechanism records read; neither names the other or a shared clearance route.
- both records name GHRHR
- both increases it
- at least one acts through it rather than binding it, so this is additive rather than duplicated
Two compounds pushing the same node the same way. Whether that is wanted depends on the node.
Derived from the two records’ own mechanism fields. No study administered them together.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
- a curated rule names the mechanism
- The canonical GHRH + ghrelin-mimetic pairing, routinely combined and sold pre-blended. Its rationale is that the two act at different receptors on one axis; the somatostatin-suppression step that argument rests on has not been measured for ipamorelin specifically, and no study has given the two together. Same-syringe compatibility is a separate question the syringe planner answers.
Theoretical synergy: the mechanism is argued from the records. No study has administered the combination.
Derived from the two records’ own mechanism fields. No study administered them together.
- both records carry an adverse effect by the same mechanism: GH-driven sodium and water retention at the renal tubule
Effects sharing a mechanism are expected to add.
On record — a curated pair, a label, or a study of the combination.
CJC-1295 no-DAC + MK-6772 conflicts
Both mechanism records read; neither names the other or a shared clearance route.
- both records name GHRHR
- both increases it
- at least one acts through it rather than binding it, so this is additive rather than duplicated
Two compounds pushing the same node the same way. Whether that is wanted depends on the node.
Derived from the two records’ own mechanism fields. No study administered them together.
No shared receptor acting in the same direction, so there is nothing to be redundant with.
Both target sets read; no directional edge runs between these two.
- a curated rule names the mechanism
- Different receptors on the same axis: a GHRH analog raises pulse amplitude while a ghrelin mimetic raises pulse frequency and is expected to suppress somatostatin. Pairing one of each is the standard secretagogue protocol. No study has administered the combination and measured the result, and the somatostatin step is inferred from the class rather than measured for these compounds.
Theoretical synergy: the mechanism is argued from the records. No study has administered the combination.
Derived from the two records’ own mechanism fields. No study administered them together.
- both records carry an adverse effect in the same organ system (cardiovascular)
- but they are different effects: Transient flushing after injection / Congestive heart failure reported in a frail elderly hip-fracture population
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
Ipamorelin + MK-6773 conflicts
Both mechanism records read; neither names the other or a shared clearance route.
- both records name GHSR
- both bind it and increases its signal
- receptor duplication rather than a new mechanism
The second adds load at the same place rather than acting somewhere new.
Derived from the two records’ own mechanism fields. No study administered them together.
- both records name GHSR
- both bind it and increases its signal
- receptor duplication rather than a new mechanism
- but the records differ: different route (intravenous infusion vs oral); different half-life (approximately 2 hours vs approximately 24 hours)
Same target, different exposure — the second is not simply the first again.
Derived from the two records’ own mechanism fields. No study administered them together.
Both target sets read; no directional edge runs between these two.
Both target sets read; no shared destination reached by different routes.
- both records carry an adverse effect in the same organ system (renal and fluid balance)
- but they are different effects: Water retention / peripheral oedema / Fluid retention and peripheral oedema
Shared organ system, different effects and no shared mechanism. This is a burden on one system, not an additive effect.
On record — a curated pair, a label, or a study of the combination.
Every pair 10
BPC-157 + TB-500no conflict on record
The most commonly reported repair pairing: different mechanisms (BPC-157 is gut-derived and angiogenesis-modulating; TB-500 is an actin-binding fragment supporting cell migration). No interaction is on record; the pairing's popularity is community practice, not trial evidence.
curated pair — complementary mechanisms, no interaction on record.
Records: BPC-157 · TB-500 · same-vial question: syringe planner
BPC-157 + CJC-1295 no-DACnothing on record
No pair rule, no class rule and no record covers this combination. That is a statement about our records, not about safety.
Records: BPC-157 · CJC-1295 no-DAC · same-vial question: syringe planner
BPC-157 + Ipamorelinsame direction
Both records move GASTRIC_MOTILITY the same way, so the two add rather than conflict. That is often the point of putting them together; what it is not is a measured total — no study has given them at once, so how much they add, and whether more is better here, is not on record.
BPC-157 raises it; Ipamorelin raises it.
derived from the two records' own mechanism fields — no study administered them together.
Records: BPC-157 · Ipamorelin · same-vial question: syringe planner
BPC-157 + MK-677nothing on record
No pair rule, no class rule and no record covers this combination. That is a statement about our records, not about safety.
Records: BPC-157 · MK-677 · same-vial question: syringe planner
TB-500 + CJC-1295 no-DACnothing on record
No pair rule, no class rule and no record covers this combination. That is a statement about our records, not about safety.
Records: TB-500 · CJC-1295 no-DAC · same-vial question: syringe planner
TB-500 + Ipamorelinnothing on record
No pair rule, no class rule and no record covers this combination. That is a statement about our records, not about safety.
Records: TB-500 · Ipamorelin · same-vial question: syringe planner
TB-500 + MK-677nothing on record
No pair rule, no class rule and no record covers this combination. That is a statement about our records, not about safety.
Records: TB-500 · MK-677 · same-vial question: syringe planner
CJC-1295 no-DAC + Ipamorelinworks together in theory
The canonical GHRH + ghrelin-mimetic pairing, routinely combined and sold pre-blended. Its rationale is that the two act at different receptors on one axis; the somatostatin-suppression step that argument rests on has not been measured for ipamorelin specifically, and no study has given the two together. Same-syringe compatibility is a separate question the syringe planner answers.
curated pair — the ghrh × ghrp class rule on its best-known instance; mechanism argued, combination untested.
Records: CJC-1295 no-DAC · Ipamorelin · same-vial question: syringe planner
CJC-1295 no-DAC + MK-677works together in theory
Different receptors on the same axis: a GHRH analog raises pulse amplitude while a ghrelin mimetic raises pulse frequency and is expected to suppress somatostatin. Pairing one of each is the standard secretagogue protocol. No study has administered the combination and measured the result, and the somatostatin step is inferred from the class rather than measured for these compounds.
class rule — the textbook GH-pulse model, argued rather than demonstrated.
Records: CJC-1295 no-DAC · MK-677 · same-vial question: syringe planner
Ipamorelin + MK-677caution
Two ghrelin mimetics drive the same GHS-R receptor. This includes MK-677 alongside an injectable GHRP — oral route does not change the receptor.
class rule — receptor duplication.
Records: Ipamorelin · MK-677 · same-vial question: syringe planner
Injection burden
23–58 injections a week across the 4 injected compounds whose records carry a frequency.
MK-677: no injectable route on file — doses, but not injections.
Some of these can share a draw, which lowers the real count — the syringe planner works that out per pair.